Magnesium

Magnesium is a cofactor for more than 300 enzymatic reactions, including those involved in energy metabolism, protein synthesis, and nerve signal regulation. Deficiency is common in older adults and in people with poor diets, gut absorption problems, or certain medications, which is the population most represented in supplementation trials.

A 2021 systematic review and meta-analysis of oral magnesium for insomnia in older adults pooled 3 randomized controlled trials with 151 total participants and found magnesium supplementation reduced sleep onset latency by 17.36 minutes compared to placebo (95% CI -27.27 to -7.44, P=0.0006) and improved total sleep time by roughly 16 minutes [1]. Those are real, statistically significant numbers. They also come from only 3 small trials, all rated at moderate-to-high risk of bias, with the review's own authors grading the supporting evidence low to very low quality using the GRADE framework. On cognition, a 2024 systematic review and meta-analysis (3,812 records screened, 3 RCTs and 12 cohort studies included) did not attempt to pool the 3 RCTs quantitatively because there were too few and they were too heterogeneous in population and magnesium form [2]. One of those trials, in adults over 65, found a significantly greater improvement in Montreal Cognitive Assessment score with magnesium glycinate versus placebo (2.3 vs 0.5 points, P=0.01), with a much weaker effect in participants under 65.

What the evidence does not show: in that same 2024 review, a separate RCT using magnesium-L-threonate, the form most heavily marketed for brain-specific effects based on rodent studies showing it crosses into brain tissue more readily, found no significant improvement in cognitive status at 6-month follow-up in a trial of 34 women undergoing breast cancer procedures. The review's overall conclusion was that evidence remains insufficient to draw firm conclusions about magnesium supplements for cognition, that dietary magnesium findings were inconsistent, and that only serum magnesium level itself, not supplementation, showed a consistent U-shaped association with dementia risk (both low and high serum levels carried elevated risk), graded at moderate confidence. A U-shaped observational association is not the same claim as a supplementation trial showing benefit, and the review explicitly did not equate the two.

No confirmed Blueprint page lists a specific standing magnesium dose or form as part of the official protocol at the time of this review, so no self-experimentation claim is attributed here pending a direct source check.

A 2022 dose-response meta-analysis of 19 prospective cohort studies with over 1.16 million participants and 52,378 deaths found that higher dietary magnesium intake was associated with lower all-cause mortality (pooled effect size 0.87, 95% CI 0.79-0.97, P=0.009) and cancer mortality, with each additional 100 mg/day of dietary magnesium linked to a 6% lower all-cause mortality risk [3]. Critically, the same meta-analysis found no significant association between supplemental or total magnesium intake and all-cause, cardiovascular, or cancer mortality. Only the dietary-source signal held up. That is a meaningful distinction the supplement industry rarely makes clear: getting magnesium from food correlates with better outcomes in cohort data, but taking a magnesium pill on top of an already adequate diet has not shown the same mortality association.

Critics of magnesium's sleep and cognition marketing point out that most positive trials recruit older adults, a population more likely to have a baseline magnesium insufficiency that supplementation corrects, and that this is a different claim than magnesium improving sleep or cognition in someone who is not deficient. The magnesium-L-threonate premium marketing claim in particular rests heavily on rodent brain-penetration data that has not been matched by a correspondingly large human cognitive trial.

The honest takeaway: magnesium supplementation shows a real, modest, statistically significant sleep benefit in older adults based on a small evidence base, dietary (not supplemental) magnesium correlates with lower mortality in cohort data, and the cognition picture is too thin and mixed to support the confident specific-form marketing claims sold around it.

The 8 supplemental forms. Magnesium is sold as at least eight different salts and chelates, and the endpoint evidence is form-specific rather than shared. Magnesium glycinate (bisglycinate) is 14.1% elemental magnesium and holds the only positive randomized sleep trial: 155 adults over 4 weeks improved the Insomnia Severity Index by 1.6 points more than placebo, p=0.049, Cohen's d=0.20, at 250 mg/day elemental [4]. The same form has a pregnancy leg-cramp trial in which 86.0% versus 60.5% of women reached a 50% cramp reduction, p=0.007, number needed to treat 3.9 [5]. Magnesium L-threonate is 8.25% elemental, the lowest density of the eight, and is the only form with a cognition trial as its primary endpoint: 100 adults aged 18 to 45 over 6 weeks, NIH Total Cognition Composite p=0.043, reaction time p=0.031, with fluid intelligence null at p=0.953 [6]. Magnesium citrate is 16.16% elemental and holds the migraine result: 600 mg/day for 12 weeks cut attack frequency 41.6% versus 15.8% on placebo, p<0.05, at the cost of 18.6% diarrhea [7]. Citrate also produced the highest serum and salivary magnesium in a 46-person, 60-day randomized comparison, while oxide showed no difference from placebo [8]. Magnesium malate is 15.54% elemental and has no proven cognitive or energy endpoint in humans; the blinded phase of its only randomized study reported no clear treatment effect [9]. Magnesium taurate has no human trial at all, only a 30-rat blood pressure experiment. Magnesium oxide is 60.30% elemental, the highest of the eight, and the worst absorbed at roughly 4% fractional absorption [10]; its one solid indication is constipation, where 1,500 mg/day compound for 28 days produced 70.6% overall improvement versus 25.0% on placebo, p=0.015 [11]. Magnesium chloride is 25.53% elemental and holds the depression result: 248 mg/day elemental for 6 weeks improved PHQ-9 by a net 6.0 points adjusted, p<0.001, with effects visible within 2 weeks [12], plus an insulin-sensitivity signal of HOMA-IR 3.8 versus 5.0, p=0.005 [13]. Magnesium sulfate is 20.19% elemental on an anhydrous basis and has no oral longevity indication; its evidence base is parenteral obstetric use.

Compound weight is not elemental magnesium. A label reading 2,200 mg magnesium glycinate delivers about 310 mg elemental magnesium, a 7.1-fold gap, because glycinate is 14.1% magnesium by weight. The Supplement Facts panel is required to declare elemental magnesium; front-of-bottle copy frequently quotes compound weight instead [14]. The multiplier differs by salt, which is why a stated milligram figure means nothing without the salt name.

The ceiling. The EC Scientific Committee on Food set a tolerable upper intake level of 250 mg/day of supplemental elemental magnesium, with a no-observed-adverse-effect level of 250 mg/day and mild diarrhea at roughly 360 to 365 mg/day [15]. Several of the endpoint trials above deliberately exceed that ceiling, and their diarrhea rates are the visible cost.

Products with this: Magnesium